-+ 0.00%
-+ 0.00%
-+ 0.00%

Fate Therapeutics reports early Phase 1 FT836 data showing tumor shrinkage in KRAS wild-type metastatic colorectal cancer without conditioning chemo

PUBT·06/01/2026 12:33:38
Listen to the news
Fate Therapeutics reports early Phase 1 FT836 data showing tumor shrinkage in KRAS wild-type metastatic colorectal cancer without conditioning chemo
  • Fate Therapeutics presented preliminary Phase 1 data for off-the-shelf CAR T-cell candidate FT836 at the 2026 ASCO annual meeting.
  • Early results showed tumor shrinkage signals in heavily pre-treated KRAS wild-type metastatic colorectal cancer without conditioning chemotherapy.
  • Safety profile appeared favorable, with no severe immune-related toxicities reported in the initial patient set.
  • Drug cells were detected in blood and later in tumor tissue, supporting trafficking and functional persistence without lymphodepletion.
  • Company signaled a strategic focus on KRAS wild-type colorectal cancer as enrollment continues.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010830PRIMZONEFULLFEED9729439) on June 01, 2026, and is solely responsible for the information contained therein.